ArticleTranslational stroke research2018
Vinpocetine Inhibits NF-κB-Dependent Inflammation in Acute Ischemic Stroke Patients.
Article in Translational stroke research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02878772 (Vinpocetine Inhibits NF-κB-dependent Inflammation in Acute Ischemic Stroke), which is not on this map. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Vinpocetine Inhibits NF-κB-dependent Inflammation in Acute Ischemic Stroke
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it, 78 citations in OpenAlex.
- Comparative efficacy of neuroprotective agents for improving neurological function and prognosis in acute ischemic stroke: a network meta-analysis.Frontiers in neuroscience · 2024Pooled it
- Argatroban Increased the Basal Vein Drainage and Improved Outcomes in Acute Paraventricular Ischemic Stroke Patients.Medical science monitor : international medical journal of experimental and clinical research · 2020Trial
- Functional improvement and immune-inflammatory cytokines profile of ischaemic stroke patients after treatment with boswellic acids: a randomized, double-blind, placebo-controlled, pilot trial.Inflammopharmacology · 2019Trial
- Vinpocetine-An "Old" Drug with a New Face: Moving Toward a Better Understanding of Its Neuroprotective Mechanism of Action.Biomolecules · 2026Review
- Interleukin‑6 and ischemic stroke: From mechanisms to clinical prospects (Review).Molecular medicine reports · 2026Review
- "The emerging role of lymphocytes in post-stroke inflammation: A treatable target and review of current pharmacological evidence in humans".Brain, behavior, & immunity - health · 2026Review
- MicroRNA-9-5p Alleviates Oxidative Stress, Inflammation, and Apoptosis in Cerebral Ischemia-reperfusion Injury by Targeting NOX4Current molecular medicine · 2026Article
- Activation of Inflammasomes and Relevant Modulators for the Treatment of Microglia-mediated Neuroinflammation in Ischemic Stroke.Molecular neurobiology · 2024Review
- Synthesis and pharmacological activity of vinpocetine derivatives.RSC advances · 2024Review
- Attenuated effects of topical vinpocetine in an imiquimod-induced mouse model of psoriasis.Journal of Taibah University Medical Sciences · 2024Article
- Exploring Chinese herbal medicine for ischemic stroke: insights into microglia and signaling pathways.Frontiers in pharmacology · 2024Review
- Clinical Pharmacology of Vinpocetine: Properties Revisited and Introduction of a Population Pharmacokinetic Model for Its Metabolite, Apovincaminic Acid (AVA).Pharmaceutics · 2023Article
- A Review on Natural Antioxidants for Their Role in the Treatment of Parkinson's Disease.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Thromboinflammatory challenges in stroke pathophysiology.Seminars in immunopathology · 2023Review
- Neuroprotective effects of vinpocetine, as a phosphodiesterase 1 inhibitor, on long-term potentiation in a rat model of Alzheimer's disease.BMC neuroscience · 2023Article
- Phytochemicals as Immunomodulatory Agents in Melanoma.International journal of molecular sciences · 2023Review
- Regulation of Microglia-Activation-Mediated Neuroinflammation to Ameliorate Ischemia-Reperfusion Injury via the STAT5-NF-κB Pathway in Ischemic Stroke.Brain sciences · 2022Article
- Cyclic GMP modulating drugs in cardiovascular diseases: mechanism-based network pharmacology.Cardiovascular research · 2022Review
- The PI3K/AKT Pathway-The Potential Key Mechanisms of Traditional Chinese Medicine for Stroke.Frontiers in medicine · 2022Review
- Acute Inflammation in Cerebrovascular Disease: A Critical Reappraisal with Focus on Human Studies.Life (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunity and inflammation play critical roles in the pathogenesis of acute ischemic stroke. Therefore, immune intervention, as a new therapeutic strategy, is worthy of exploration. Here, we tested the inflammation modulator, vinpocetine, for its effect on the outcomes of stroke. For this multi-center study, we recruited 60 patients with anterior cerebral circulation occlusion and onset of stroke that had exceeded 4.5 h but lasted less than 48 h. These patients, after random division into two groups, received either standard management alone (controls) or standard management plus vinpocetine (30 mg per day intravenously for 14 consecutive days, Gedeon Richter Plc., Hungary). Vinpocetine treatment did not change the lymphocyte count; however, nuclear factor kappa-light-chain-enhancer of activated B cell activation was inhibited as seen not only by the increased transcription of IκBα mRNA but also by the impeded phosphorylation and degradation of IκBα and subsequent induction of pro-inflammatory mediators. These effects led to significantly reduced secondary lesion enlargement and an attenuated inflammation reaction. Compared to controls, patients treated with vinpocetine had a better recovery of neurological function and improved clinical outcomes during the acute phase and at 3-month follow-up. These findings identify vinpocetine as an inflammation modulator that could improve clinical outcomes after acute ischemic stroke. This study also indicated the important role of immunity and inflammation in the pathogenesis of acute ischemic stroke and the significance of immunomodulatory treatment. CLINICAL TRIAL REGISTRATION INFORMATION: www.clinicaltrials.gov . Identifier: NCT02878772.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.